SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-41661

Jin Medical International Ltd.

(Exact name of registrant as specified in its charter)

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K (“Report”) shall be deemed to be incorporated by reference into the registration statement on F-3 (File No. 333-288314) of Jin Medical International Ltd., a Cayman Islands exempted company (the “Company”), initially filed with the U.S. Securities and Exchange Commission on June 25, 2025 (“Registration Statement”), and into each prospectus or prospectus supplement outstanding under the Registration Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

EXPLANATORY NOTE

Results of 2026 Extraordinary General Meeting of Shareholders

The 2026 Extraordinary General Meeting of Shareholders (the “Meeting”) of Jin Medical International Ltd. (the “Company”) was held at the Company’s principal office at No. 33 Lingxiang Road, Wujin District, Changzhou City, Jiangsu Province, People’s Republic of China, on January 30, 2026 at 9:00 a.m. EST.

At the close of business on December 30, 2025, the record date for the determination of holders of the ordinary shares of the Company (the “Ordinary Shares”) entitled to vote at the Meeting, there were 156,547,100 Ordinary Shares issued and outstanding on December 30, 2025. All Ordinary Shares shall have one vote per share. At the Meeting, the holders of 128,595,806.60 Ordinary Shares of the Company were represented in person or by proxy, exceeding one-third of the total Ordinary Shares entitled to vote at the Meeting and constituting a quorum.

Capitalized terms not otherwise defined herein have the meaning given to them in the notice of the Meeting and the proxy statement, which were filed as exhibits to the Company’s Current Report on Form 6-K with the U.S. Securities and Exchange Commission on January 8, 2026 (File No. 001-41661).

At the Meeting, the shareholders of the Company adopted the following resolutions:

1. The shareholders voted to approve by way of a special resolution, with immediate effect, that:

2. The shareholders voted to approve by way of a special resolution, that, subject to and immediately following the Change of Authorized Share Capital being approved and effected, the Company adopt the second amended and restated memorandum and articles of association (“A&R M&A”), substantially in the form of Appendix A attached hereto, in substitution for, and to the exclusion of, the Company’s existing amended and restated memorandum and articles of association, to reflect the creation of a dual class share capital structure following the Change of Authorized Share Capital.

3. The shareholders voted to approve by way of an ordinary resolution, that subject to and immediately following the Change of Authorized Share Capital being approved and effected:

4. The shareholders voted to approve by way of an ordinary resolution that the Company adopt the 2026 Equity Incentive Plan (the “Plan”), substantially in the form attached hereto as Appendix B, and that the Board be granted the authority to issue up to a maximum of 13,000,000 Class A Ordinary Shares pursuant to the Plan as equity awards to certain directors, officers, managers, employees, consultants and advisors (and prospective directors, officers, managers, employees, consultants and advisors) of the Company and its affiliates, with the exact allocation and timing of grants to be determined at the sole discretion of the Board in accordance with the terms and conditions set forth in the Plan.

5. The shareholders voted to approve by way of an ordinary resolution to adjourn the Meeting to a later date or dates or sine die, if necessary.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 4, 2026